Article & News

The US President Donald J Trump’s proclamation imposing 100% tariff on patented pharmaceuticals and their ingredients may have limited impact on the Indian pharma industry

India could soon get a lot thinner – at least in theory.On Friday the patent on semaglutide – the molecule behind Danish drugmaker Novo Nordisk’s

Hetero launches its generic semaglutide portfolio in international markets, enhancing access to advanced diabetes and obesity therapies. Hetero has launched its generic semaglutide portfolio in

Ultra-low dose of cancer meds works, reduces costs by 90%, finds Tata studyThe Parel-based premier cancer hospital found that giving one-tenth of the standard dosage

The eagerly anticipated semaglutide patent cliff in India has unleashed a strikingly varied pricing landscape. The intensity of the price decline is driven by the

New Delhi: Medicine prices in India may rise sharply amid a 30% surge in the cost of key raw materials or active pharma ingredients in

With the patent protection for Novo Nordisk’s best-selling medicine semaglutide expiring in India, at least eight Indian companies on Saturday launched cheaper, generic versions of

Hyderabad-based Natco Pharma has launched its generic semaglutide injection in India at a starting price of Rs 1,290 per month, marking one of the cheapest

Mumbai: Doctors in India are increasingly testing “dose optimisation” to make high-cost treatments affordable while cutting side-effects, and Tata Memorial Hospital’s latest findings underline how

As India enters 2026, its medical devices sector stands at an inflection point. The convergence of targeted manufacturing incentives, regulatory consolidation, and sustained healthcare demand